Indacaterol/glycopyrronium bromide

Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board

Retrieved on: 
Wednesday, May 25, 2022
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, Regenerative medicine, Department, Measuring Business Excellence, International Congress on Tuberculosis, Company, Achievement, Allergic rhinitis, Research, Vision, New Drug Application, 2021 Essex County Council election, Distinguishing, Therapy, NEJM, Asthma, COVID-19, Translation, Leading, FDA, IND, Indacaterol/glycopyrronium bromide, International development, Corporation, Cell, Coronavirus Scientific Advisory Board (Turkey), Hero, Drug, Neurotherapeutics, Medical device, Pharmaceutical industry, COPD, Novartis, Development

Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Companys Scientific Advisory Board.

Key Points: 
  • Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Companys Scientific Advisory Board.
  • I am pleased to welcome Dr. Banerji to our Scientific Advisory Board.
  • Success in the area of regenerative medicine requires deep knowledge of the complicated scientific, biological and clinical issues associated with developing a living drug.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
  • Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Organic compounds, Combination drugs, Indacaterol/glycopyrronium bromide, Quaternary ammonium compounds, Tertiary alcohols, Glycopyrronium bromide, Chronic obstructive pulmonary disease, Indacaterol, COPD: Journal of Chronic Obstructive Pulmonary Disease

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro Breezhaler (an inhaled once-daily fixed-dose combination of indacaterol/glycopyrronium bromide) has been included in the 2019 National Reimbursement Drug List (NRDL) in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • The list is approved nationally with the aim of providing basic medical coverage to China's population of 1.4 billion.
  • Glycopyrronium bromide and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019

Retrieved on: 
Wednesday, May 1, 2019
Health, Biotechnology, Pharmaceutical, Chronic lower respiratory diseases, Pulmonology, Medicine, Respiratory system, RTT, Chronic obstructive pulmonary disease, Bronchitis, Respiratory disease, Sunovion, Indacaterol/glycopyrronium bromide, Obstructive lung disease

Sunovion Pharmaceuticals Inc. (Sunovion) will present data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019 (ATS 2019), taking place May 17-22, 2019 in Dallas, Texas.

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) will present data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019 (ATS 2019), taking place May 17-22, 2019 in Dallas, Texas.
  • LONHALA MAGNAIR is used long term, twice each day (morning and evening), for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
  • LONHALA MAGNAIR does not relieve sudden symptoms of COPD and should not be used more than twice daily.
  • Do not use LONHALA MAGNAIR if you are allergic to glycopyrrolate or to any of the ingredients in LONHALA MAGNAIR.

Sosei Heptares Announces that Ultibro® Breezhaler® and Seebri® Breezhaler® Launched in China for the Treatment of COPD

Retrieved on: 
Thursday, March 21, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Chemistry, Combination drugs, Glycopyrronium bromide, Pyrrolidines, Indacaterol/glycopyrronium bromide, Novartis

TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro Breezhaler and Seebri Breezhaler have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro Breezhaler and Seebri Breezhaler have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • Both products are approved and launched in over 90 countries worldwide, including the US, EU and Japan.
  • Huizheng has applied to include Ultibro Breezhaler and Seebri Breezhaler in the National Health Insurance Drug List.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Announces that Ultibro® Breezhaler® and Seebri® Breezhaler® Launched in China for the Treatment of COPD

Retrieved on: 
Thursday, March 21, 2019
Drugs, Chemical compounds, Muscarinic antagonists, Chemistry, Combination drugs, Glycopyrronium bromide, Pyrrolidines, Indacaterol/glycopyrronium bromide, Novartis

TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro Breezhaler and Seebri Breezhaler have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • TOKYO and LONDON, March 21, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro Breezhaler and Seebri Breezhaler have been launched by Novartis in China for the treatment of chronic obstructive pulmonary disease (COPD).
  • Both products are approved and launched in over 90 countries worldwide, including the US, EU and Japan.
  • Huizheng has applied to include Ultibro Breezhaler and Seebri Breezhaler in the National Health Insurance Drug List.
  • "Sosei Heptares" is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).